Targeting transmembrane TNF-α suppresses breast cancer growth
- PMID: 23794706
- DOI: 10.1158/0008-5472.CAN-12-3946
Targeting transmembrane TNF-α suppresses breast cancer growth
Abstract
TNF antagonists may offer therapeutic potential in solid tumors, but patients who have high serum levels of TNF-α fail to respond to infliximab, suggesting consumption of the circulating antibody and loss of transmembrane TNF-α (tmTNF-α) on tumors by ectodomain shedding. Addressing this possibility, we developed a monoclonal antibody (mAb) that binds both full-length tmTNF-α and its N-terminal truncated fragment on the membrane after tmTNF-α processing but does not cross-react with soluble TNF-α. We documented high levels of tmTNF-α expression in primary breast cancers, lower levels in atypical hyperplasia or hyperplasia, but undetectable levels in normal breast tissue, consistent with the notion that tmTNF-α is a potential therapeutic target. Evaluations in vitro and in vivo further supported this assertion. tmTNF-α mAb triggered antibody-dependent cell-mediated cytotoxicity against tmTNF-α-expressing cells but not to tmTNF-α-negative cells. In tumor-bearing mice, tmTNF-α mAb delayed tumor growth, eliciting complete tumor regressions in some mice. Moreover, tmTNF-α mAb inhibited metastasis and expression of CD44v6, a prometastatic molecule. However, the antibody did not activate tmTNF-α-mediated reverse signaling, which facilitates tumor survival and resistance to apoptosis, but instead inhibited NF-κB activation and Bcl-2 expression by decreasing tmTNF-α-positive cells. Overall, our results established that tmTNF-α mAb exerts effective antitumor activities and offers a promising candidate to treat tmTNF-α-positive tumors, particularly in patients that are nonresponders to TNF antagonists.
©2013 AACR.
Similar articles
-
Expression of TNF-alpha leader sequence renders MCF-7 tumor cells resistant to the cytotoxicity of soluble TNF-alpha.Breast Cancer Res Treat. 2009 Jul;116(1):91-102. doi: 10.1007/s10549-008-0111-5. Epub 2008 Jul 10. Breast Cancer Res Treat. 2009. PMID: 18618239
-
Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells.Oncogene. 2018 Jun;37(25):3456-3470. doi: 10.1038/s41388-018-0221-4. Epub 2018 Mar 21. Oncogene. 2018. PMID: 29559745 Free PMC article.
-
Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2.J Immunol. 2014 Feb 1;192(3):1320-31. doi: 10.4049/jimmunol.1203195. Epub 2013 Dec 30. J Immunol. 2014. PMID: 24379122
-
Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.J Immunother Cancer. 2023 Jan;11(1):e003837. doi: 10.1136/jitc-2021-003837. J Immunother Cancer. 2023. PMID: 36720496 Free PMC article.
-
Tumor Necrosis Factor-α, a Regulator and Therapeutic Agent on Breast Cancer.Curr Pharm Biotechnol. 2016;17(6):486-94. doi: 10.2174/1389201017666160301102713. Curr Pharm Biotechnol. 2016. PMID: 26927216 Review.
Cited by
-
Infliximab enhances the therapeutic effects of 5-fluorouracil resulting in tumor regression in colon cancer.Onco Targets Ther. 2016 Oct 3;9:5999-6008. doi: 10.2147/OTT.S109342. eCollection 2016. Onco Targets Ther. 2016. PMID: 27757041 Free PMC article.
-
Anti-cancer effects of polyphenol-rich sugarcane extract.PLoS One. 2021 Mar 10;16(3):e0247492. doi: 10.1371/journal.pone.0247492. eCollection 2021. PLoS One. 2021. PMID: 33690618 Free PMC article.
-
Antitumor necrosis factor-α antibodies as a noveltherapy for hepatocellular carcinoma.Exp Ther Med. 2018 Aug;16(2):529-536. doi: 10.3892/etm.2018.6235. Epub 2018 May 30. Exp Ther Med. 2018. PMID: 30116311 Free PMC article.
-
Xanthomicrol: Effective therapy for cancer treatment.Toxicol Rep. 2023 Feb 21;10:436-440. doi: 10.1016/j.toxrep.2023.02.008. eCollection 2023. Toxicol Rep. 2023. PMID: 37102154 Free PMC article. Review.
-
The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches.Cell Oncol (Dordr). 2020 Feb;43(1):1-18. doi: 10.1007/s13402-019-00489-1. Epub 2020 Jan 3. Cell Oncol (Dordr). 2020. PMID: 31900901 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical